Compare Sana Biotechnology Inc (SANA) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Schlumberger NV — how do they compare? Sana Biotechnology Inc trades at $2.84 (market cap $836.71M), while Schlumberger NV trades at $48.95 (market cap $72.69B). The key difference: Schlumberger NV is far larger — about 86.9× Sana Biotechnology Inc's market cap, and Schlumberger NV pays a 2.41% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Schlumberger NV for 99 Days on average.
| SANA | SLB | |
|---|---|---|
Market Cap | $836.71M | $72.69B |
Volume | 4,507,444 | 16,228,451 |
Sector | Health | Energy |
52-Week High | $5.92 | $60.10 |
52-Week Low | $2.68 | $31.72 |
Typical Hold Time | 23 Days | 99 Days |
Enterprise Value | $749.96M | $81.42B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
SLB trades at $48.91, up 1.98% today, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 8.53% net margin and 13.37% ROE, supported by recent contract wins in Saudi Arabia and Mozambique. Revenue declined slightly to $35.71B in 2025, but operating cash flow remains robust at $6.49B. Analyst consensus is strongly bullish with 85% buy ratings and $64.58 price target, representing 32% upside potential.
SLB presents a compelling value opportunity with strong fundamentals and positive analyst sentiment, though technical indicators suggest near-term weakness. The stock's current valuation at 23.89 P/E appears reasonable given the company's contract momentum and global energy technology leadership. Key risks include energy price volatility and execution challenges in new projects, but the dividend yield and institutional support provide downside protection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
